NovaBay Pharmaceuticals (NBY) Company Report

NovaBay Pharmaceuticals, Inc. (NBY) completed a private placement on January 16, 2026, raising approximately $134 million through the issuance of pre-funded warrants to purchase 837,696,130 shares of common stock, which represent approximately 87% of the total outstanding common stock.
The company has adopted a new blockchain-based asset acquisition strategy, primarily focused on acquiring SKY tokens, and as of the private placement closing, held 943,599,688.812 SKY.
In connection with the private placement, key investors received nomination rights for the Board of Directors and consent rights over material changes to the company's Digital Asset Strategy.
Effective January 1, 2026, NBY adopted new accounting guidance (ASU No. 2023-08) to measure eligible crypto assets at fair value, with changes recognized in net income.

Jan 16, 2026, 10:27 PM

NovaBay Pharmaceuticals Regains NYSE American Listing Compliance

NBY

Delisting/Listing Issues

Convertible Preferred Issuance

NovaBay Pharmaceuticals, Inc. (NBY) regained compliance with the NYSE American’s continued listing standards, as formally confirmed by the NYSE American in a letter dated October 20, 2025.
The company had previously been notified on April 18, 2024, and May 28, 2024, of non-compliance with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide, which require a minimum of $6 million in stockholders' equity.
To address these deficiencies, NovaBay issued and sold pre-funded warrants, generating approximately $6.0 million in net proceeds, and issued and sold Series E non-voting convertible preferred stock, generating approximately $2.15 million in net proceeds.
Following these transactions, the company believes its stockholders’ equity now exceeds the $6 million minimum requirement.